Related references
Note: Only part of the references are listed.Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
Farhad Ravandi et al.
CANCER (2017)
Therapy for Older AML Patients: The Role of Novel Agents and Allogeneic Stem Cell Transplant
Jeffrey E. Lancet et al.
Journal of the National Comprehensive Cancer Network (2017)
Guadecitabine for AML and MDS: hype or hope?
Mohamed A. Kharfan-Dabaja
LANCET ONCOLOGY (2015)
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
Jean-Pierre J. Issa et al.
LANCET ONCOLOGY (2015)
Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Competing risks
Jason Fine et al.
LIFETIME DATA ANALYSIS (2014)
Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure
Thomas Prebet et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Competing Risk of Death: An Important Consideration in Studies of Older Adults
Sarah D. Berry et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
